Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial

[1]  A. Falcão,et al.  Effect of opicapone on levodopa pharmacokinetics, catechol‐O‐methyltransferase activity and motor fluctuations in patients with Parkinson's disease , 2015, European journal of neurology.

[2]  Susan H Fox,et al.  Clinical spectrum of levodopa‐induced complications , 2015, Movement disorders : official journal of the Movement Disorder Society.

[3]  A. Falcão,et al.  Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations , 2014, European Journal of Clinical Pharmacology.

[4]  G. Tomlinson,et al.  Another face of placebo: The lessebo effect in Parkinson disease , 2014, Neurology.

[5]  W. Poewe,et al.  Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release , 2014, Parkinson's disease.

[6]  S. Lidstone.  Great expectations: the placebo effect in Parkinson's disease. , 2014, Handbook of experimental pharmacology.

[7]  L. Kiss,et al.  CHAPTER 4:Catechol‐O‐Methyl‐Transferase Inhibitors: Present Problems and Relevance of the New Ones , 2013 .

[8]  A. Berardelli,et al.  Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease , 2013, European journal of neurology.

[9]  Maria João Bonifácio,et al.  Computation of the binding affinities of catechol‐O‐methyltransferase inhibitors: Multisubstate relative free energy calculations , 2012, J. Comput. Chem..

[10]  Guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease , 2012 .

[11]  Barbara Stanley,et al.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. , 2011, The American journal of psychiatry.

[12]  Regina Katzenschlager,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[13]  W. Poewe,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[14]  R. Hauser,et al.  Determination of minimal clinically important change in early and advanced Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[15]  Maria João Bonifácio,et al.  Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. , 2010, Journal of medicinal chemistry.

[16]  V. Preedy,et al.  Unified Parkinson's Disease Rating Scale , 2010 .

[17]  W. Brannath,et al.  A graphical approach to sequentially rejective multiple test procedures , 2009, Statistics in medicine.

[18]  W. Poewe.  Treatments for Parkinson disease—past achievements and current clinical needs , 2009, Neurology.

[19]  C. Sampaio,et al.  Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease , 2008, Clinical neuropharmacology.

[20]  Paolo Barone,et al.  The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[21]  Xin Wang,et al.  Tree‐structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectives , 2007, Statistics in medicine.

[22]  G. Deuschl,et al.  Effect of medical and surgical interventions on health‐related quality of life in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[23]  Fabrizio Stocchi,et al.  Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications , 2006, The Lancet Neurology.

[24]  W Poewe,et al.  Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.

[25]  Laurent Gerbaud,et al.  Impact of the motor complications of Parkinson's disease on the quality of life , 2005, Movement disorders : official journal of the Movement Disorder Society.

[26]  C. Clarke,et al.  Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. , 2004, The Cochrane database of systematic reviews.

[27]  C Trenkwalder,et al.  The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[28]  S Fahn,et al.  Committee. Unified Parkinson’s Disease Rating Scale. , 2001 .

[29]  Marjan Jahanshahi,et al.  What contributes to quality of life in patients with Parkinson's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[30]  L. Seeberger,et al.  A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia , 2000, Clinical neuropharmacology.

[31]  J. Harper,et al.  Catechol-O-methyltransferase inhibitors in Parkinson's disease , 1998, The Lancet.

[32]  R. Fitzpatrick,et al.  PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures , 1998, Journal of Neurology.

[33]  Ronald J. Faber,et al.  Compulsive buying: descriptive characteristics and psychiatric comorbidity. , 1994, The Journal of clinical psychiatry.

[34]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[35]  S. Fahn.  Unified Parkinson's Disease Rating Scale , 1987 .

[36]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .